| scholarly article | Q13442814 |
| P50 | author | Douglas B. Johnson | Q88381068 |
| Sunandana Chandra | Q88381071 | ||
| P2093 | author name string | Jeffrey A Sosman | |
| Elizabeth J Davis | |||
| P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
| The Sequence of the Human Genome | Q22065842 | ||
| Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction | Q24315032 | ||
| BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib | Q38954343 | ||
| Whole-genome landscapes of major melanoma subtypes. | Q39060449 | ||
| Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. | Q39174229 | ||
| First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. | Q39388286 | ||
| Mechanisms and prevention of UV-induced melanoma | Q39432336 | ||
| Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial | Q39537308 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma | Q40082486 | ||
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| BRAF inhibitor activity in V600R metastatic melanoma | Q42713820 | ||
| Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Q45070125 | ||
| Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. | Q45974368 | ||
| The Genetic Evolution of Melanoma from Precursor Lesions | Q46079642 | ||
| BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas | Q46878710 | ||
| Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. | Q47107863 | ||
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. | Q47824495 | ||
| Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. | Q50906889 | ||
| BRAF inhibitor activity in V600R metastatic melanoma--response. | Q54444220 | ||
| Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 | ||
| Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma | Q58024726 | ||
| Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report | Q68100559 | ||
| The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma | Q84066786 | ||
| Molecular genetics of neurofibromatosis type 1 (NF1) | Q24518449 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| A landscape of driver mutations in melanoma | Q24603357 | ||
| Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma | Q24607661 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Pathways and therapeutic targets in melanoma | Q26865736 | ||
| Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification | Q27851656 | ||
| BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors | Q27851843 | ||
| Elucidating distinct roles for NF1 in melanomagenesis | Q27851952 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin | Q27852360 | ||
| Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy | Q27852482 | ||
| Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines | Q27852814 | ||
| Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence | Q27852894 | ||
| Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial | Q27853021 | ||
| The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF | Q27853045 | ||
| TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma | Q27853068 | ||
| Crizotinib in ROS1-rearranged non-small-cell lung cancer. | Q27853075 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| CANCER. The odds of immunotherapy success | Q28268271 | ||
| Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials | Q28730438 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. | Q30967043 | ||
| Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials | Q31143336 | ||
| BRAF and NRAS mutations in melanoma and melanocytic nevi | Q33250357 | ||
| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden | Q33576170 | ||
| Germline p16 mutations in familial melanoma | Q34059915 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Q34551403 | ||
| Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence | Q34555510 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation | Q34965452 | ||
| Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions | Q35083710 | ||
| Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies | Q35154039 | ||
| Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin | Q35752935 | ||
| Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion | Q35963400 | ||
| Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. | Q36173439 | ||
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | Q36338753 | ||
| RAC1 P29S regulates PD-L1 expression in melanoma. | Q36362336 | ||
| An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background | Q36464502 | ||
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q36730827 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents | Q37004819 | ||
| Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas | Q37028299 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Genome-wide association study identifies three loci associated with melanoma risk | Q37341178 | ||
| Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma | Q37473978 | ||
| Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | Q37598084 | ||
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy | Q37606223 | ||
| An immunogenic personal neoantigen vaccine for patients with melanoma | Q38692859 | ||
| RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. | Q38704201 | ||
| Melanocytic nevi and melanoma: unraveling a complex relationship | Q38730348 | ||
| MYC regulates the antitumor immune response through CD47 and PD-L1 | Q38787131 | ||
| NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics | Q38925098 | ||
| Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. | Q38942785 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3490-3499 | |
| P577 | publication date | 2018-04-17 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Melanoma: What do all the mutations mean? | |
| P478 | volume | 124 |
| Q89579593 | An NRAS mutation in primary malignant melanoma of the lung: a case report |
| Q90303580 | BRAF V600E mutational load as a prognosis biomarker in malignant melanoma |
| Q60960586 | Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas |
| Q114774023 | Flavonoids from Ericameria nauseosa inhibiting PI3K/AKT pathway in human melanoma cells |
| Q96304654 | Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment |
| Q98771864 | Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications |
| Q61810153 | Targeted Therapy and Immunotherapy for Melanoma in Japan |
| Q92355921 | The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts |
| Q58581282 | The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51 |
| Q94564129 | Up-Regulation of Activating Transcription Factor 3 in Human Fibroblasts Inhibits Melanoma Cell Growth and Migration Through a Paracrine Pathway |
Search more.